TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04863885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: Participants will be treated at 1 of 2 dose levels of Sacituzumab govitecan, either at 8 mg/kg, 10 mg/kg, or 6 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: Participants will be treated at 1 of 2 dose levels of Sacituzumab govitecan, either at 8 mg/kg, 10 mg/kg, or 6 mg/kg.
Study: NCT05275686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray
Description: Patients will use two sprays in each nostril twice a day for 6 weeks and additional 6 weeks (open label).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray
Description: The Placebo is made of the following ingredients: Purified Water, Microcrystalline Cellulose RC-591, Dextrose, Anhydrous, EDTA Disodium Dihydrate, Benzalkonium Chloride Solution 50%, Polysorbate 80 (Tween 80, HP-LQ-(MH)), Sodium Hydroxide, and Hydrochloric Acid. Patients will use two sprays in each nostril twice a day
Study: NCT04457141

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Effect of pelvic floor for the use of minimalist shoes versus shod in woman.
Description: Measure the activity of the pelvic floor and others muscles with EMG during treadmill running with different speeds and different shoes: minimalist and shod.

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Effect of pelvic floor for the use of minimalist shoes versus shod in woman.
Description: Measure the activity of the pelvic floor and others muscles with EMG during treadmill running with different speeds and different shoes: minimalist and shod.
Study: NCT05058794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow Restriction/Resistance Training
Description: During each exercise, only blood flow in the involved leg was restricted using an aneroid sphygmomanometer. Prior to exercise the cuff was placed on the most proximal portion of the limb and limb occlusion pressure (LOP) was calculated in the body position that the Blood flow Restriction (BFR) stimulus would be applied. Blood Flow Restriction BFR pressure was set at 50% occlusion. Resistance applied for 1 minute (60 sec) with 30 % load of 1 repetition maximum. Subjects will receive treatment bilaterally. Participants will perform exercises 2 sets with 15 repetitions through 0 to 90 degrees.
Study: NCT06563076

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular Rehabilitation
Description: supervised vestibular rehabilitation program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular Rehabilitation
Description: supervised vestibular rehabilitation program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular Electrical Stimulation
Description: 80 Hz high frequency transcutaneous vestibular electrical stimulation (VES)
Study: NCT06553157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Statins are drugs known to help lower total cholesterol and reduce the risk of a heart attack or stroke. Statins include atorvastatin , fluvastatin , lovastatin , pitavastatin , pravastatin, rosuvastatin and simvastatin.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT06679036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-2189
Description: HRS-2189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-2189
Description: HRS-2189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvustat
Description: Fluvustat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvustat
Description: Fluvustat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-8080
Description: HRS-8080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-8080
Description: HRS-8080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-6209
Description: HRS-6209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-6209
Description: HRS-6209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-6209
Description: HRS-6209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-1358
Description: HRS-1358
Study: NCT06678633

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T-Control® (experimental)
Description: Patients will receive intravesical therapy (1-2 hours) through T-Control®, a new Foley-type silicone catheter with an integrated fluid-control valve into the catheter's distal end, which has three positions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Folysil® (control)
Description: Patients will receive intravesical therapy (1-2 hours) through Folysil® Silicone catheter (Coloplast), the usual clinical practice in the participating center.
Study: NCT06679361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Exercise Program
Description: This program consists of wrist motor exercises focused on active range of motion (including flexion, extension, ulnar and radial deviation, and finger flexion) along with nerve mobilization exercises for the medial, radial, and ulnar nerves. The aim is to enhance motor function in the wrist and hand.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Exercise Program
Description: This program consists of wrist motor exercises focused on active range of motion (including flexion, extension, ulnar and radial deviation, and finger flexion) along with nerve mobilization exercises for the medial, radial, and ulnar nerves. The aim is to enhance motor function in the wrist and hand.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Exercise Group
Description: Arm Description: This group will engage in sensory exercises designed to enhance sensory awareness in the hand and wrist. Exercises will include interaction with varied textures (such as sand and sensory balls), different fabrics (fur, satin, linen), and multisensory foam gels. The goal is to improve sensory function and tactile discrimination.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Motor and Sensory Exercise Group
Description: Participants in this group will perform both motor and sensory exercises as described for the first two groups. By combining motor and sensory interventions, this group aims to improve both motor skills and sensory awareness in the wrist and hand, potentially enhancing overall hand function more effectively.
Study: NCT06678750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TKA using computer navigation
Description: TKA using Exactech GPS Newton Knee protocol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TKA
Description: TKA using manual instrumentation
Study: NCT06678815

Intervention type: OTHER
Intervention: Emergency response
Description: Those delivering or receiving emergency care from a CFR.
Study: NCT06679322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androtriol Injection (High-dose group)
Description: Participants will receive 30 mL of Androtriol Injection per dose, administered every 12 hours for 7 consecutive days. Each infusion will be administered over a period of 30±5 minutes.
Study: NCT05639751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT3789
Description: PRT3789 will be administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT3789
Description: PRT3789 will be administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered by intravenous infusion
Study: NCT05065216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human tissue kallikrein
Description: DM199 administered by a single intravenous (IV) dose followed by subcutaneous (SC) doses at 2 hours (+10 hours) of the IV dose completion and then 2 times per week up to Day 21

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for DM199 Solution for Injection
Description: Placebo administered by a single intravenous (IV) dose followed by subcutaneous (SC) doses at 2 hours (+10 hours) of the IV dose completion and then 2 times per week up to Day 21.
Study: NCT06679322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androtriol Injection (Low-dose group)
Description: Participants will receive 10 mL of Androtriol Injection combined with 20 mL of placebo (Hydroxypropyl Beta-Cyclodextrin Injection) per dose, administered every 12 hours for 7 consecutive days. Each infusion will be administered over a period of 30±5 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxypropyl-β-cyclodextrin injection
Description: Participants will receive 30 mL of Hydroxypropyl-β-cyclodextrin injection per dose, administered every 12 hours for 7 consecutive days. Each infusion will be completed within 30±5 minutes.
Study: NCT05580042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1101
Description: For each patient, once daily (QD)
Study: NCT05058794

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy Group
Description: Resistance applied for 1 minute (60 sec) with 30 % load of 1 repetition maximum. Subjects will receive treatment bilaterally.participants will perform 2 sets with 15 repetitions in (0 to 90 degree.)
Study: NCT05803967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baduanjin exercising
Description: baduanjin will be applied 5 times per the week, under supervision, for 12 weeks,
Study: NCT05541237

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food
Description: Food
Study: NCT05469789

Intervention type: OTHER
Intervention: No Intervention
Description: As it is an observational study, no intervention is administered in this study.

Intervention type: OTHER
Intervention: No Intervention
Description: As it is an observational study, no intervention is administered in this study.

Intervention type: OTHER
Intervention: No Intervention
Description: As it is an observational study, no intervention is administered in this study.
Study: NCT05747560

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Buckwheat
Description: Take buckwheat at a dose of 500 mg twice a day for 6 months.
Study: NCT06371872

Intervention type: PROCEDURE
Intervention: total transfixing injury to the rotator cuff
Description: develop an appropriate prescription strategy with a view to improving patients' quality of life in the short, medium and long term in this condition
Study: NCT06578585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Description: Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ubrogepant
Description: Tablet
Study: NCT05498909

Intervention type: OTHER
Intervention: Multidisciplinary joint diagnosis and treatment mode
Description: Multidisciplinary joint diagnosis and treatment mode,break down barriers and treat the heart and brain together
Study: NCT04600973

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Technical assistance or team-based coaching
Description: Main comparison in delivering peri-operative preventive strategies against transmission and infection is one on one technical assistance or team-based coaching.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Technical assistance or team-based coaching
Description: Main comparison in delivering peri-operative preventive strategies against transmission and infection is one on one technical assistance or team-based coaching.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Technical assistance or team-based coaching
Description: Main comparison in delivering peri-operative preventive strategies against transmission and infection is one on one technical assistance or team-based coaching.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Technical assistance or team-based coaching
Description: Main comparison in delivering peri-operative preventive strategies against transmission and infection is one on one technical assistance or team-based coaching.
Study: NCT06206837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vepdegestrant
Description: Daily oral dosages of vepdegestrant continuously, dose escalation/de-escalation in Phase 1b until recommended phase 2 dose (RP2D) determined, cycles lasting 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060
Description: Daily oral dosages of PF-07220060 continuously, dose escalation/de-escalation in Phase 1b until recommended phase 2 dose (RP2D) determined, cycles lasting 28 days
Study: NCT04430010

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BEST in CLASS
Description: BEST in CLASS is a Tier-2 evidence based program (EBP) that has demonstrated effectiveness at reducing children's Disruptive Behavior Problems (DBPs) and risk for Emotional and Behavioral Disorders (EBDs)
Study: NCT06585384

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: etanercept and repeated contrast ultrasound
Description: Strategy combining 9 weeks of etanercept administration (50mg/week) with 5 weeks of repeated contrast ultrasound of 2 sessions per day, 5 days per week (from the fifth week of etanercept treatment)
Study: NCT05380947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1810631 - trial formulation 1 (TF1)
Description: BI 1810631 - trial formulation 1 (TF1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1810631 - trial formulation 1 (TF1)
Description: BI 1810631 - trial formulation 1 (TF1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1810631 - trial formulation 1 (TF1)
Description: BI 1810631 - trial formulation 1 (TF1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1810631 - trial formulation 1 (TF1)
Description: BI 1810631 - trial formulation 1 (TF1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1810631 - new formulation (NF)
Description: BI 1810631 - new formulation (NF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1810631 - new formulation (NF)
Description: BI 1810631 - new formulation (NF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1810631 - new formulation (NF)
Description: BI 1810631 - new formulation (NF)
Study: NCT05747560

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Astragalus extract
Description: Take astragalus extract at a dose of 450 mg twice a day for 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wolfiporia extract
Description: Take wolfiporia extract product at a dose of 15 g twice a day for 6 months.
Study: NCT06391125

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal Saline
Description: 0.5ml normal saline solution added to prefilled 1.2 million units Benzathine Pencillin G syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 0.5ml 1% lidocaine solution added to prefilled 1.2 million units Benzathine Pencillin G syringe
Study: NCT06285175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-REINVENT
Description: Tele-REINVENT consists of EMG-biofeedback of the affected arm to control games on a computer screen.
Study: NCT05542342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg IV once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib Malate
Description: 100 mg orally once daily
Study: NCT05551208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluzopanib and bevacizumab
Description: fluzopanib and bevacizumab were used for maintenance treatment
Study: NCT06324383

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention (videoconferencing)
Description: 1 hour videoconferencing sessions over 8 weeks with an English language learner partner.
Study: NCT05380947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1810631 - new formulation (NF)
Description: BI 1810631 - new formulation (NF)
Study: NCT05451108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCL Pectus Scaffold implantation and autologous fat grafting
Description: A small incision is made in the chest and pre-sternal pocked is defined. Following this, an empty scaffold is implanted at the site of the defect with skin closed directly over it. At the same stage, autologous fat transfer will be performed, harvesting fat from available donor sites such as the thighs and abdomen - depending on scaffold volume and patient morphology. The area will be infiltrated with local anaesthetic tumescent fluid, liposuction performed, and fat transferred to syringes for filtration prior to injection into the scaffold. Fat will not be processed beyond simple filtration to separate liquid from fat to be injected. The scaffold provides structural stability to the chest during the infiltration of the tissue inside the scaffold.
Study: NCT06413303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experiential Classroom
Description: Experiential classroom emphasizes putting pregnant women at the center, based on their subjective willingness and previous knowledge and experience, creating an environment for free discussion, exchange, and reflection, and utilizing peer education to fully mobilize the subjective initiative of pregnant women. This approach allows them to explore, discuss, reflect, and learn autonomously, aiming to truly absorb, master, and apply theoretical knowledge.
Study: NCT04948515

Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory test
Description: genotyping of IL 17 and IL23

Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory test
Description: genotyping of IL 17 and IL23

Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory test
Description: estimation of serum level of IL 17

Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory test
Description: estimation of serum level of IL 17
Study: NCT05769309

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae block
Description: After induction, the patients will be administered bilateral Erector spinae block with 20 ml of 0.25 % bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: fentanyl boluses of 0.5-to-1 µg/kg titrated according to haemodynamic parameters.

Intervention type: DRUG
Group type: OTHER
Intervention: Fentanyl
Description: fentanyl boluses of 0.5-to-1 µg/kg titrated according to haemodynamic parameters.
Study: NCT06136195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavoglurant
Description: The 200mg mavoglurant will be administered in the form of two 100mg oral tablets. Placebo will be administered with matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavoglurant
Description: The 200mg mavoglurant will be administered in the form of two 100mg oral tablets. Placebo will be administered with matching tablets.
Study: NCT04651361

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinalbuphine sebacate
Description: Naldebain dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: Benzyl benzoate and sesame oil served as placebo solution (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
Study: NCT06556550

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic ablative radiation therapy
Description: stereotactic ablative radiation therapy in effective doses to each metastatic site

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: palliative radiation therapy
Description: palliative radiation therapy (8 Gy/1 Fx, 3 Gy x 10-15 Fx, 4,5 Gy x 5 Fx)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: prescribed drug line
Study: NCT06578585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG09222
Description: Solution for injection/infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection/infusion
Study: NCT05380947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium
Description: Rabeprazole sodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium
Description: Rabeprazole sodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium
Description: Rabeprazole sodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium
Description: Rabeprazole sodium
Study: NCT06016725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participate in online resistance training sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Given educational materials

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Given educational materials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Assessment
Description: Participate in online nutritional counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Performance Testing
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05375929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Description: Orally administered, abrocitinib 100 mg tablets QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Description: Orally administered, abrocitinib 200 mg tablets QD.